EarningsQ2 2026 Earnings Report
MX:TFX Q2 2026 EPS Results
Actual EPS$31.85
Consensus EPS$23.18
Beat/MissBeat by +$8.67
One Year Ago EPS$67.50
MX:TFX Q2 2026 Revenue Results
Actual Revenue$10.32B
Expected Revenue$10.13B
Beat/MissBeat by +$194.40M
YoY Revenue Growth-26.96%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:TFX Upcoming Earnings
Teleflex's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:TFX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.Company Guidance
Revenue and Growth Beat
Q2 continuing operations revenue $570.3M (GAAP up 28.9% YoY) with pro forma adjusted constant currency growth of 4.7%, ahead of expectations.
Segment Strength — Vascular and Surgical
Vascular revenue $246.3M, up 8.0% YoY; Surgical revenue $112.1M, up 9.2% YoY, driven by hemostatic products, central access, ligation clips, instruments and skin stapling.
Adjusted EPS and Guidance Upgrade
Q2 adjusted EPS $1.76, up 1.7% YoY and above expectations. Full-year 2026 adjusted EPS guidance raised to $6.90–$7.20 (prior $6.25–$6.55).
Strategic OEM Divestiture Closed — Significant Proceeds
Closed OEM divestiture generating approximately $1.5B of proceeds (estimated $1.25B after-tax), with majority of proceeds earmarked for $800M debt reduction and $1B share repurchase program.
Capital Return and Balance Sheet Actions
Q2 repurchased ~1.9M shares for $250M (avg $130.85). Announced additional $250M accelerated share repurchase (ASR) and used OEM proceeds to repay $700M Term Loan A-2, reducing pro forma net leverage to ~1.9x.
R&D Investment and Innovation Milestones
Increased R&D to 7.9% of sales in H1 2026. Achieved FDA BLA approval for EZPLAZ (first FDA-licensed freeze-dried plasma) and positive Freesolve clinical milestones (BIOMAG-I 4-year data favorable, BIOMAG-II enrollment completed early, BIOMAG-III pivotal trial commenced).
Margin and Expense Discipline Outlook
Maintained 2026 adjusted operating margin outlook of ~19% and reiterated steady-state operating margin target of ~23%. Launched multiyear restructuring expected to deliver ~$50M annual pretax savings by mid-2028.
Lower Net Interest Expense and Tax Rate Guidance
Full-year net interest expense outlook reduced to ~ $85M (from ~$105M) following debt paydown; adjusted tax rate guidance lowered to ~12.25% (from ~13.5%).
MX:TFX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed